Sarepta Therapeutics, Inc.
SRPT Healthcare Biotechnology
Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow SRPT
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
788.49 | 653.19 | 939.65 | 850.99 |
+8 more quarters Free account |
Receivables |
376.82 | 394.82 | 398.23 | 395.74 | |
Inventory |
904.27 | 1,001.11 | 914.74 | 1,077.17 | |
Other current assets |
154.24 | 260.76 | 285.31 | 398.41 | |
Total current assets |
2,223.82 | 2,309.88 | 2,537.94 | 2,722.31 | |
Property, Plant, Equpment (Net) |
325.99 | 336.24 | 345.13 | 358.94 | |
Long-Term Investments |
145.37 | 81.94 | 1.05 | 1.04 | |
Long-term assets (Other) |
146.15 | 151.96 | 155.55 | 73.38 | |
Total non-current assets |
964.69 | 869.06 | 811.77 | 771.13 | |
Total Assets |
3,188.51 | 3,178.93 | 3,349.70 | 3,493.44 | |
Accounts Payable |
50.98 | 70.38 | 280.84 | 94.02 | |
Accrued Expenses |
325.23 | 302.37 | 359.66 | 295.79 | |
Current Revenue (Deferred) |
110.13 | 116.04 | 443.40 | 485.45 | |
Other current liabilities |
16.56 | 10.38 | 11.39 | 46.17 | |
Total current liabilities |
502.91 | 499.16 | 1,095.29 | 921.43 | |
Long Term Debt (Total) |
847.62 | 838.16 | 828.97 | 1,035.15 | |
Non-current Revenue (Deferred) |
110.13 | 136.35 | 83.91 | — | |
Non-current Liabilities (Other) |
1.83 | 1.65 | 1.53 | 1.70 | |
Total non-current liabilities |
1,157.81 | 1,174.67 | 1,113.79 | 1,251.89 | |
Total liabilities |
1,660.71 | 1,673.83 | 2,209.08 | 2,173.32 | |
Additional Paid In Capital |
6,104.53 | 6,076.50 | 6,042.59 | 5,986.69 | |
Common Stock (Net) |
0.01 | 0.01 | 0.01 | 0.01 | |
Retained Earnings |
(4,550.91) | (4,546.02) | (4,876.98) | (4,641.54) | |
Treasury Stock |
25.26 | 25.26 | 25.26 | 25.26 | |
Common Equity (Total) |
1,527.80 | 1,505.10 | 1,140.62 | 1,320.12 | |
Shareholders Equity (Total) |
1,527.80 | 1,505.10 | 1,140.62 | 1,320.12 | |
Shareholders Equity and Liabilities (Total) |
3,188.51 | 3,178.93 | 3,349.70 | 3,493.44 | |
Shares (Common) |
105.62 | 105.57 | 104.96 | 104.77 | |
Shareholders Equity (Tangible) |
1,527.80 | 1,505.10 | 1,140.62 | 1,320.12 | |
Net Debt |
59.13 | 184.97 | (110.68) | 184.15 | |
Total Debt |
847.62 | 838.16 | 828.97 | 1,035.15 |